olaparib,abiraterone
merck,astrazeneca
['crpc', 'brca', 'brcaaway']
brcaaway: ph 2 trial of abi (arm 1), olap (arm 2), or abi + olap (arm 3) in mcrpc with dna repair defects (n=61) 43 pts w/ traes (most common fatigue, n=23) psa decline: 79% arm 1, 81% arm 2, 90% arm 3 arm 3: mpfs and 12-mo pfs rate vs arm 1 &amp; 2 #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday